Keyphrases
Placebo-controlled
100%
Phase II Trial
100%
Duchenne muscular Dystrophy
100%
Drisapersen
100%
Placebo
55%
6-minute Walk Distance (6MWD)
44%
Difference in Mean
22%
Off-treatment
22%
Adverse Events
11%
Randomized Placebo-controlled Trial
11%
Pharmacokinetics
11%
Phase II Study
11%
Steady State
11%
Patient Benefit
11%
Proteinuria
11%
Efficacy Endpoint
11%
Change from Baseline
11%
Tolerability
11%
Muscle Strength
11%
Pulmonary Function Test
11%
Positive Responses
11%
Persistent Effects
11%
Safety Self-efficacy
11%
Injection Site Reaction
11%
Timed Tests
11%
Long Half-life
11%
Strength Function
11%
Dosage Regimen
11%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Duchenne Muscular Dystrophy
100%
Drisapersen
100%
Adverse Event
11%
Tolerability
11%
Proteinuria
11%
Injection Site Reaction
11%
Pharmacokinetics
11%